Regulatory T cells in pregnancy disorders: a multi-dimensional framework for biomarkers and therapeutic strategies

Ning Zhang1, Jun Zhou1, Wenxue Ma2

  • 1Department of Obstetrics, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.

Pregnancy represents a unique immunological state in which the maternal immune system must maintain tolerance toward the semi-allogeneic fetus while preserving protective immunity against pathogens. Regulatory T cells (Tregs) are central to this balance, coordinating immune suppression, tissue remodeling, and vascular adaptation throughout gestation. Increasing evidence implicates Treg dysregulation in pregnancy disorders, including recurrent pregnancy loss, preeclampsia, and spontaneous preterm labor. Notably, pathological alterations extend beyond changes in cell abundance and involve multi-dimensional defects in suppressive function, lineage stability, spatial distribution, and regulatory signaling. Advances in high-dimensional immune profiling, including single-cell, spatial, and multi-omics approaches have revealed substantial heterogeneity in Treg populations at the maternal-fetal interface and enabled identification of immune signatures with diagnostic and prognostic potential. These insights are reshaping biomarker development from static measurements toward functionally and spatially resolved immune profiling. In this review, we propose a stage-specific and multi-dimensional framework for understanding Treg biology in pregnancy and systematically compare Treg alterations across major pregnancy disorders. We further evaluate the translational potential of circulating and decidual Treg signatures as biomarkers and discuss emerging therapeutic strategies aimed at restoring immune tolerance. Taken together, this framework positions Treg biology as a foundation for biomarker-guided diagnosis and mechanism-based therapeutic interventions in pregnancy complications.

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...